Hanish Sharma
All India Institute of Medical Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hanish Sharma.
Gut | 2012
Ramesh Kumar; Shalimar; Hanish Sharma; Rohit Goyal; Ajay Kumar; Shankar Khanal; Shyam Prakash; S. Datta Gupta; Subrat Kumar Panda; Subrat K. Acharya
Objective It is difficult to predict the outcome in patients with acute liver failure (ALF) using existing prognostic models. This study investigated whether early changes in the levels of dynamic variables can predict outcome better than models based on static baseline variables. Design 380 patients with ALF (derivation cohort n=244, validation cohort n=136) participated in a prospective observational study. The derivation cohort was used to identify predictors of mortality. The ALF early dynamic (ALFED) model was constructed based on whether the levels of predictive variables remained persistently high or increased over 3 days above the discriminatory cut-off values identified in this study. The model had four variables: arterial ammonia, serum bilirubin, international normalised ratio and hepatic encephalopathy >grade II. The model was validated in a cohort of 136 patients with ALF. Results The ALFED model demonstrated excellent discrimination with an area under the receiver operator characteristic curve of 0.91 in the derivation cohort and of 0.92 in the validation cohort. The model was well calibrated in both cohorts and showed a similar increase in mortality with increasing risk scores from 0 to 6. The performance of the ALFED model was superior to the Kings College Hospital criteria and the Model for End stage Liver Disease score, even when their 3-day serial values were taken into consideration. An ALFED score of ≥4 had a high positive predictive value (85%) and negative predictive value (87%) in the validation cohort. Conclusion The ALFED model accurately predicted outcome in patients with ALF, which may be useful in clinical decision-making.
Journal of Gastroenterology and Hepatology | 2014
Govind K. Makharia; Chris J. Mulder; Khean-Lee Goh; Vineet Ahuja; Julio C. Bai; Carlo Catassi; Peter H. Green; Siddhartha Datta Gupta; Knut E.A. Lundin; Ramakrishna Bs; Ramakant Rawat; Hanish Sharma; Ajit Sood; Chikako Watanabe; Peter R. Gibson
Once thought to be uncommon in Asia, coeliac disease (CD) is now being increasingly recognized in Asia–Pacific region. In many Asian nations, CD is still considered to be either nonexistent or very rare. In recognition of such heterogeneity of knowledge and awareness, the World Gastroenterology Organization and the Asian Pacific Association of Gastroenterology commissioned a working party to address the key issues in emergence of CD in Asia.
Journal of Gastroenterology and Hepatology | 2013
Rohit Goyal; Saumya Ranjan Mallick; Mousumi Mahanta; Saurabh Kedia; Shalimar; Rajan Dhingra; Hanish Sharma; Prasenjit Das; Siddhartha Datta Gupta; Subrat Kumar Panda; Subrat K. Acharya
Liver fibrosis is an established determinant of prognosis and therapy in chronic hepatitis B (CHB). The role of fibroscan in assessing fibrosis in CHB remains unclear. Present study was designed to correlate fibroscan with liver biopsy and determine whether fibroscan can avoid liver biopsy in patients with CHB.
Clinical Gastroenterology and Hepatology | 2012
Ramesh Kumar; Shalimar; Hanish Sharma; Shyam Prakash; Subrat Kumar Panda; Shankar Khanal; Subrat K. Acharya
BACKGROUND & AIMS Patients admitted to the hospital with acute liver failure (ALF) and high arterial levels of ammonia are more likely to have complications and poor outcomes than patients with lower levels of ammonia. ALF is a dynamic process; ammonia levels can change over time. We investigated whether early changes (first 3 days after admission) in arterial levels of ammonia were associated with complications and outcomes and identified factors associated with persistent hyperammonemia. METHODS We performed a prospective observational study that measured arterial ammonia levels each day for 5 days in 295 consecutive patients with ALF. We analyzed associations of changes in ammonia levels during the first 3 days with complications and outcomes. RESULTS Patients with persistent arterial hyperammonemia (≥122 μmol/L for 3 consecutive days), compared with those with decreasing levels, had lower rates of survival (23% vs 72%; P < .001) and higher percentages of cerebral edema (71% vs 37%; P < .001), infection (67% vs 28%; P = .003), and seizures (41% vs 7.7%; P < .001). Patients with persistent hyperammonemia had greater mortality, with an odds ratio (OR) of 10.7, compared with patients with baseline levels of ammonia ≥122 μmol/L (OR, 2.4). Patients with persistent hyperammonemia were more likely to progress to and maintain advanced hepatic encephalopathy than those with decreasing levels. Patients with persistent, mild hyperammonemia (≥85 μmol/L for 3 days) were also more likely to have complications or die (P < .001) than patients with serial ammonia levels <85 μmol/L. Infections (OR, 4.17), renal failure (OR, 2.20), and decreased arterial pH (OR, 0.003) were independent predictors of persistent hyperammonemia. CONCLUSIONS Patients with ALF and persistent arterial hyperammonemia for 3 days after admission are more likely to develop complications and have greater mortality than patients with decreasing levels or high baseline levels. Infection, renal failure, and decreased arterial pH are independent predictors of persistent hyperammonemia.
Journal of clinical and experimental hepatology | 2014
Ashish Kumar; Subrat K. Acharya; Shivaram Prasad Singh; Vivek A. Saraswat; Anil Arora; Ajay Duseja; Goenka Mk; Deepali Jain; Premashish Kar; Manoj Kumar; Vinay Kumaran; Kunisshery Mallath Mohandas; D. K. Panda; Shashi Bala Paul; Hariharan Ramesh; P.N. Rao; Samir Shah; Hanish Sharma; Ragesh Babu Thandassery
Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality and healthcare expenditure in patients with chronic liver disease. There are no consensus guidelines on diagnosis and management of HCC in India. The Indian National Association for Study of the Liver (INASL) set up a Task-Force on HCC in 2011, with a mandate to develop consensus guidelines for diagnosis and management of HCC, relevant to disease patterns and clinical practices in India. The Task-Force first identified various contentious issues on various aspects of HCC and these issues were allotted to individual members of the Task-Force who reviewed them in detail. The Task-Force used the Oxford Center for Evidence Based Medicine-Levels of Evidence of 2009 for developing an evidence-based approach. A 2-day round table discussion was held on 9th and 10th February, 2013 at Puri, Odisha, to discuss, debate, and finalize the consensus statements. The members of the Task-Force reviewed and discussed the existing literature at this meeting and formulated the INASL consensus statements for each of the issues. We present here the INASL consensus guidelines (The Puri Recommendations) on prevention, diagnosis and management of HCC in India.
Alimentary Pharmacology & Therapeutics | 2015
Shashi Bala Paul; Shalimar; Vishnubhatla Sreenivas; Shivanand Gamanagatti; Hanish Sharma; Ekta Dhamija; Subrat K. Acharya
Frequency of hepatocellular carcinoma (HCC) in hepatic venous outflow tract obstruction (HVOTO) is unclear and risk factors in HVOTO associated with HCC are unknown.
Journal of clinical and experimental hepatology | 2014
Shashi Bala Paul; Hanish Sharma
Transcatheter intra-arterial therapies play a vital role in treatment of HCC due to the unique tumor vasculature. Evolution of techniques and newer efficacious modalities of tumor destruction have made these techniques popular. Various types of intra-arterial therapeutic options are currently available. These constitute: bland embolization, trans-arterial chemotherapy, trans-arterial chemo embolization with or without drug-eluting beads and trans-arterial radio embolization, which are elaborated in this review.
Alimentary Pharmacology & Therapeutics | 2016
Shalimar; Ajay Kumar; Saurabh Kedia; Hanish Sharma; Shivanand Gamanagatti; Gurpreet Singh Gulati; Baibaswata Nayak; Bhaskar Thakur; Subrat K. Acharya
Results of endovascular interventions in hepatic venous outflow tract obstruction (HVOTO) have been reported from limited studies. Treatment outcomes and prognostic scores need further validation.
Journal of clinical and experimental hepatology | 2014
Hanish Sharma
Diagnosis at advanced disease stage and early vascular invasion are the bane of majority of patients with hepatocellular carcinoma (HCC) in India. The currently standardized curative and palliative treatment modalities [surgery, ablative techniques, trans-catheter chemotherapy, systemic chemotherapy] are suboptimal for a significant proportion of disease stages. Interest in radiotherapy for hepatocellular carcinoma has seen a resurgence with revolutionary improvements in targeting radiation doses safely. Encouraging results have been reported with a host of radiation techniques from conformal radiotherapy, stereotactic whole body radiation therapy to charged particle based therapies. The dissemination of this knowledge has been slow across other specialties involved in care of patients with HCC. However the increasing availability of radiotherapy services predicts a hopeful future for wider evaluation of radiotherapy in HCC.
Journal of Digestive Diseases | 2015
Hanish Sharma; Anil K Verma; Prasenjit Das; Siddhartha Dattagupta; Vineet Ahuja; Govind K. Makharia
The clinical spectrum of celiac disease (CeD) is wide and its symptoms overlap with those of functional bowel diseases. This study aimed to investigate the relationship among gluten‐related disorders, irritable bowel syndrome (IBS) and uninvestigated dyspepsia in Indian patients.